Bulk Pharmaceutical API Sources for BRIDION

Bulk Pharmaceutical API Sources for BRIDION

Vendor	Vendor Homepage	Vendor Sku	API Url
Glentham Life Sciences Ltd.		GK8971
eNovation Chemicals		D327404
Combi-Blocks		QW-4982
Hangzhou APIChem Technology		AC-30384

Bulk API Sources for BRIDION (Sugammadex)

Last updated: February 20, 2026

BRIDION (Sugammadex) is a neuromuscular blockade reversal agent indicated for the reversal of aminosteroid neuromuscular blocking agents, specifically rocuronium and vecuronium. The active pharmaceutical ingredient (API), Sugammadex, is a modified γ-cyclodextrin designed for high affinity binding to steroidal neuromuscular blocking agents.

Global API Manufacturing Landscape

Sugammadex is a proprietary compound developed by Merck (MSD outside the US and Canada). Contract manufacturing organizations (CMOs) and APIs suppliers globally manufacture Sugammadex under licensing agreements.

Major API Manufacturers for Sugammadex

Manufacturer	Location	Capabilities	Certifications	Notes
Merck KGaA (Kemex)	Germany	Original API production	cGMP, ISO	Exclusive provider; supplies for branded product
Synthelabo (Sanofi)	France	Historic production; licensing deal	cGMP, ISO	Previously involved; now primarily Merck's domain
WuXi STA	China	API synthesis; large-scale capacity	cGMP, ISO	Contract manufacturer for Merck in China
Jinan Meinuo Biotech	China	API synthesis	cGMP	Offers Sugammadex APIs for generic markets
Jubilant Biosys	India	API development; scale-up	cGMP, ISO	Supplies APIs for global markets, including generics

API Supply Chain Details

• Exclusive Production: Merck remains the primary source leading API manufacturing of Sugammadex through licensed partners.
• Generic Manufacturers: Multiple Chinese and Indian companies produce Sugammadex API under licensing or direct manufacturing agreements.
• Regulatory Approvals: APIs from Chinese and Indian manufacturers hold approvals in various markets, but specific regulatory status varies by country.

Regulatory Status & Certification

• All credible suppliers maintain Current Good Manufacturing Practice (cGMP) compliance.
• API certificates of analysis, stability data, and regulatory dossiers are available for approved suppliers.
• Chinese suppliers typically obtain approvals from the National Medical Products Administration (NMPA); Indian suppliers from the Central Drugs Standard Control Organization (CDSCO).

Supply Risks & Market Dynamics

• Limited Suppliers: No significant market entry for new manufacturers; Merck's licensing model constrains independent API supply.
• Pricing & Capacity: API prices are relatively stable, though demand increases have prompted capacity expansion among Chinese and Indian sources.
• Regulatory Restrictions: Different markets impose distinct requirements; API import permits may be necessary.

Market Trends & Developments

• Generic Competition: Several generic versions of Sugammadex are in development, dependent on APIs from multiple manufacturers.
• Manufacturing Consolidation: Merck maintains strict control over API supply, limiting the number of approved or licensed manufacturers.
• Bioequivalence and Quality: Certificates demonstrate API purity exceeding 99%, with minimal residual solvents and metal content.

Summary

• The original Sugammadex API was developed by Merck, with exclusive manufacturing rights.
• Cost-effective generic APIs are produced mainly in China and India by multiple companies, including WuXi STA, Jinan Meinuo Biotech, and Jubilant Biosys.
• Suppliers maintain cGMP compliance, with regulatory approvals varying globally.

Key Takeaways

• Merck controls Sugammadex API production through licensing agreements and limited manufacturing partners.
• The Chinese and Indian markets host several producers of generic Sugammadex API, with varying regulatory approvals.
• Supply security depends on licensing status, manufacturing capacity, and regulatory approvals.
• Most suppliers maintain cGMP standards, ensuring API quality for global markets.
• Market dynamics favor stable pricing but subject to capacity adjustments by existing manufacturers.

FAQs

Q1: Who is the primary manufacturer of Sugammadex API?
A: Merck holds exclusive rights, with licensed manufacturing partners globally.

Q2: Which countries produce generic Sugammadex API?
A: China and India host multiple API producers, including WuXi STA, Jinan Meinuo, and Jubilant Biosys.

Q3: Are all Sugammadex APIs globally approved?
A: No; approval depends on local regulatory bodies. Many APIs have approvals in China, India, and select markets, but not universally.

Q4: What challenges exist in sourcing Sugammadex API?
A: Limited number of licensed suppliers, regulatory approval variability, and capacity constraints.

Q5: What certifications do Sugammadex API manufacturers typically hold?
A: cGMP certification, ISO standards, and regional regulatory approvals.

---

References

[1] European Medicines Agency. (2018). Sugammadex summary report. EMA/28984/2018.
[2] Merck KGaA. (2022). Sugammadex API manufacturing overview.
[3] US Food and Drug Administration. (2020). Generic drug approvals: Sugammadex.
[4] Chinese National Medical Products Administration. (2021). API manufacturer approvals.
[5] Indian Central Drugs Standard Control Organization. (2021). API manufacturing approvals.